Glenn Bennett-The Wave Mp3
Rosy Coonradt
Many of our studies involve a range of in vitro, ex vivo, in vivo, and in-silico experiments on conditional mouse knockout strains that serve as a model for physiological and/or pathologic changes in protein glycosylation. Techniques used include ECG and echocardiographic measurements, optical mapping of voltage and Ca2+ waves across the epicardium, primary/immortal cell culture methods, ion channel electrophysiological studies, histology, Ca2+ handling and cellular contractility measurements, Ca2+ spark measurements, action potential measurements, and protein/glycan biochemistry using a combination of purification methods, gel electrophoresis, lectin biology, immunocytochemistry, basic confocal microscopy, and molecular biology.
The first air races, meets, and flight exhibitions kicked off a wave of public enthusiasm for aviation that circled the globe. The aviators who flew ever higher, faster, and farther were great heroes to the public during this era. These events set the stage for a new age shaped by the new reality of human flight.
We present a high-power, pulsed Nd:YAG master oscillator-power amplifier (MOPA) system consisting of a passively Q-switched, short-cavity oscillator and a series of three self-imaging planar waveguide amplifiers. This unique laser architecture produced 375 W output power at 20 kHz PRF with 1.6 ns pulse duration and 18% electrical-to-optical efficiency.
The authorization of Covaxin has also offered opportunities to monitor how well the clinical trial results translate into a real-world setting. Additionally, an effort to monitor AEs and COVID-19 cases following vaccine rollout reported that most side effects were mild and that cases were rare, even though these data would seem to have been collected during the severe wave of COVID-19 brought on by the Delta VOC in India in early 2021; at the same time, the sample sizes were extremely small (114). Similarly, larger studies of adults (June to September 2021) (115) and adolescents (beginning in January 2022) (116) who received the vaccine outside a trial setting reported that safety was similar across age groups, with no severe AEs reported for adults and with no serious AEs reported for adolescents, although 0.9% (6 individuals) reported severe AEs. However, a much lower effectiveness (22 to 29%) was estimated in a real-world setting during an analysis of cases in health care workers from April to May 2021 (117). All the same, monitoring of hospitalized COVID-19 patients between April and June 2021 indicated that the vaccines were highly effective in preventing severe illness (118).
Based on promising results of laboratory animal testing, Abdala moved to phase I/II trials in human subjects ages 19 to 80, recruiting participants between December 2020 and February 2021 (210). The three-dose vaccine elicited no serious AEs across either phase I or II, and the vaccine was found to produce a strong immune response (210). In March 2021, phase III trials began (211), and by June, officials were reporting the VE to be 92.28% (212, 213). This high efficacy estimate, along with the short timeline of data collection, initially elicited skepticism, especially given that the data were not made public (214). However, the trials were designed to enroll a large number of participants and were carried out during a wave of infections due to the arrival of variants carrying the D614G mutation in Cuba, which would be expected to allow an expedited timeline for interim analysis (214). Based on the reported results, Abdala gained emergency use authorization in Cuba in July 2021 (215), and by December 2021, cases in Cuba had dropped dramatically (216). The results of the phase III trial were posted to medRxiv in September 2022, describing the results of a randomized, placebo-controlled, multicenter, double-blind investigation of the Abdala vaccine candidate in 48,000 participants between 22 March and 3 April 2021 (217). The final results included 42 symptomatic cases of COVID-19 among participants in the placebo condition, compared to only 11 cases among participants who received the vaccine, yielding the reported VE of 92.28% (217). In terms of secondary endpoints, the VEs were 91.96% against mild/moderate COVID-19, 94.46% against severe COVID-19, and 100% against critical illness and death (217). The vaccine was also found to be very safe, with the overall incidence of AEs only 2.5% in vaccine recipients, compared to 1.9% in the placebo recipients (217). Therefore, the phase III trial suggests that this vaccine is highly effective and safe.
The impact of Wednesday's signing will spread waves throughout the Highlanders athletic program, and no two athletes may have been better for the school to celebrate on its first such signing day celebration.
Marie writes: The West Coast is currently experiencing a heat wave and I have no air conditioning. That said, and despite it currently being 80F inside my apartment, at least the humidity is low. Although not so low, that I don't have a fan on my desk and big glass of ice tea at the ready. My apartment thankfully faces East and thus enjoys the shade after the sun has crossed the mid-point overhead. And albeit perverse in its irony, it's because it has been so hot lately that I've been in the mood to watch the following film again and which I highly recommend to anyone with taste and a discerning eye.
Single-photon sources have recently been demonstrated using a variety of devices, including molecules, mesoscopic quantum wells, colour centres, trapped ions and semiconductor quantum dots. Compared with a Poisson-distributed source of the same intensity, these sources rarely emit two or more photons in the same pulse. Numerous applications for single-photon sources have been proposed in the field of quantum information, but most--including linear-optical quantum computation--also require consecutive photons to have identical wave packets. For a source based on a single quantum emitter, the emitter must therefore be excited in a rapid or deterministic way, and interact little with its surrounding environment. Here we test the indistinguishability of photons emitted by a semiconductor quantum dot in a microcavity through a Hong-Ou-Mandel-type two-photon interference experiment. We find that consecutive photons are largely indistinguishable, with a mean wave-packet overlap as large as 0.81, making this source useful in a variety of experiments in quantum optics and quantum information.
0aad45d008